Rallybio Corp. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Rallybio Corporation is holding its 2024 Annual Meeting of Stockholders on May 15, 2024, to elect directors and ratify auditors.</b>

AI Summary

Rallybio Corp (RLYB) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Rallybio Corporation will hold its 2024 Annual Meeting of Stockholders on May 15, 2024, at 9:00 a.m. ET. The meeting will be conducted virtually at www.virtualshareholdermeeting.com/RLYB2024. Stockholders will vote on the election of four Class III directors: Wendy K. Chung, Robert Hopfner, Ronald Hunt, and Hui Liu. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024, will be ratified. The record date for determining stockholders entitled to vote is March 19, 2024.

Why It Matters

For investors and stakeholders tracking Rallybio Corp, this filing contains several important signals. Stockholders have the opportunity to vote on the composition of the Board of Directors, influencing the company's strategic direction. The ratification of the independent auditor is a standard corporate governance procedure that ensures financial transparency and accountability.

Risk Assessment

Risk Level: low — Rallybio Corp shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes disclosed.

Analyst Insight

Stockholders should review the director nominees and auditor ratification proposals before the May 15, 2024 meeting.

Key Numbers

• 2024-05-15 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
• 2024-03-19 — Record Date (Stockholders entitled to vote)
• 2023-12-31 — Fiscal Year End (Fiscal year for auditor ratification)

Key Players & Entities

• Rallybio Corp (company) — Registrant
• Wendy K. Chung (person) — Director nominee
• Robert Hopfner (person) — Director nominee
• Ronald Hunt (person) — Director nominee
• Hui Liu (person) — Director nominee
• Deloitte & Touche LLP (company) — Independent registered public accounting firm
• Nasdaq (company) — Stock exchange ticker
• RLYB (company) — Stock ticker

FAQ

Industry Context

Rallybio Corporation operates in the pharmaceutical preparations industry, focusing on developing therapies.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs proxy solicitations.

What Investors Should Do

1. Review the biographies and qualifications of the director nominees.
2. Consider the independence and qualifications of Deloitte & Touche LLP.
3. Vote by the deadline to ensure your proxy is counted.

Key Dates

• 2024-05-15: 2024 Annual Meeting of Stockholders — Vote on director nominees and auditor ratification.
• 2024-03-19: Record Date — Determines stockholders eligible to vote.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, following the typical proxy statement format for corporate governance matters.

Filing Documents

• a2024_rlybxproxy.htm (DEF 14A) — 422KB
• image.jpg (GRAPHIC) — 3KB
• img114804231_0a.jpg (GRAPHIC) — 32KB
• rlyb_2024proxycard001.jpg (GRAPHIC) — 119KB
• rlyb_2024proxycard002.jpg (GRAPHIC) — 101KB
• 0001739410-24-000045.txt (&nbsp;) — 775KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 MANAGEMENT AND CORPORATE GOVERNANCE 11 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 21 AUDIT COMMITTEE REPORT 30 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 31 PROPOSAL NO. 1-ELECTION OF DIRECTORS 32 PROPOSAL NO. 2-RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 33 GENERAL MATTERS 35 -3- Rallybio Corporation 234 Church Street, Suite 1020 New Haven, CT 06510 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held On May 15, 2024 at 900 a.m. Eastern Time This proxy statement, along with the accompanying Notice of the 2024 Annual Meeting of Stockholders, contains information about the 2024 Annual Meeting of Stockholders of Rallybio Corporation, which we refer to as the Annual Meeting, including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting in a virtual meeting format on May 15, 2024 at 900 a.m. Eastern Time, at www.virtualshareholdermeeting.comRLYB2024. In this proxy statement, we refer to Rallybio Corporation as "Rallybio," the Company," "we" and "us." This proxy statement relates to the solicitation of proxies by our Board of Directors for use at the Annual Meeting. On or about April 11, 2024, we began mailing this proxy statement and proxy card (the "Proxy Materials") to all stockholders entitled to vote at the Annual Meeting. Although not part of this proxy statement, we have also made available with this proxy statement our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Annual Report"), which includes our financial statements for the fiscal year ended December 31, 2023. Proxies will be solicited by mail. We will make arrangements with brokerage houses and other custodians, nominees and fiduciaries to send proxies and proxy materials to the beneficial owners of the shares and will reimburse them for their expenses in so doing. Proxies may be solic

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information as of March 31, 2024 (unless otherwise specified), with respect to the beneficial ownership of our common stock by each person who is known to own beneficially more than 5% of the outstanding shares of common stock, each person currently serving as a director, each nominee for director, each named executive officer (as set forth in the Summary Compensation Table below), and all directors and executive officers as a group. Shares of common stock subject to options, restricted stock units or other rights to purchase which are now exercisable or are exercisable within 60 days after March 31, 2024 are to be considered outstanding for purposes of computing the percentage ownership of the persons holding these options or other rights but are not to be considered outstanding for the purpose of computing the percentage ownership of any other person. The shares underlying pre-funded warrants issued by the Company in November 2022, which are exercisable for 3,333,388 shares of common stock, are not considered outstanding for the purpose of computing the percentage ownership of any person. As of March 31, 2024, there were 37,811,970 shares of common stock outstanding and the percentage of shares beneficially owned in the table below is based on shares outstanding as of March 31, 2024. Unless otherwise indicated, the address for each director and named executive officer is co Rallybio Corporation, 234 Church Street, Suite 1020, New Haven, CT 06510. Name of Beneficial Owner Number of Shares Beneficially Owned Percentage of Shares Beneficially Owned 5% or Greater Stockholders Entities associated with Viking Global Investors LP (1) 4,194,777 11.1 % Entities affiliated with 5AM Ventures (2) 3,630,724 9.6 % Entities affiliated with New Leaf Venture Partners (3) 3,301,603 8.7 % Entities affiliated with TPG Inc. (4) 3,028,414 8.0 % FMR LLC (5) 2,535,571 6.7 % En

View Full Filing

View this DEF 14A filing on SEC EDGAR